Remove Clinical Research Remove Research Remove Research Laboratories
article thumbnail

Keytruda/Lenvima combo shows promise in hard-to-treat cancers

The Pharma Data

“These new data from our LEAP clinical program show encouraging activity across several aggressive cancer types and expand our knowledge about the potential of KEYTRUDA plus LENVIMA to help a range of patients with these cancers,” said Scot Ebbinghaus, vice president, Clinical Research, Merck Research Laboratories.

article thumbnail

Could Keytruda/Lenvima Combo Help Treat Advanced Renal Cell Carcinoma?

The Pharma Data

It is very clear that in this study, the addition of ipilimumab did not add clinical benefit but did add toxicity. Merck and Eisai are committed to working together to continue to explore the potential of the KEYTRUDA plus LENVIMA combination, particularly in areas of great unmet need such as renal cell carcinoma.”. “We

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

FDA Approves Updated Indication for Merck’s KEYTRUDA® (pembrolizumab) for Treatment.

The Pharma Data

“While the treatment landscape has evolved, an unmet need remains for appropriate patients newly diagnosed with certain types of advanced urothelial carcinoma who are not eligible for platinum-containing chemotherapy,” said Dr. Scot Ebbinghaus, vice president, clinical research, Merck Research Laboratories. “We

article thumbnail

BioSpace Movers & Shakers, Nov. 20

The Pharma Data

Hyman currently serves as director of the Stanley Center for Psychiatric Research at the Broad Institute of MIT and Harvard and is the Harvard University Distinguished Service Professor of Stem Cell and Regenerative Biology. Evenstad served as chief executive officer of Upsher-Smith Laboratories.

article thumbnail

Positive EU CHMP Opinion for Updated Label of KEYTRUDA® (pembrolizumab)

The Pharma Data

“KEYTRUDA has become an important treatment option for certain patients with locally advanced or metastatic bladder cancer in the European Union and other countries around the world,” said Dr. Scot Ebbinghaus, vice president, clinical research, Merck Research Laboratories. “We

article thumbnail

BioSpace Movers & Shakers, Dec. 18

The Pharma Data

He previously spent more than a decade at Medtronic in the company ’ s Minimally Invasive Therapies Group where he served as the global vice president and General Manager of General Surgery, and in various roles working on research, development, and strategy. He spent 27 years at Merck & Co. Immune Regulation – U.K.-based

article thumbnail

Informed Design of Bioanalytical PCR Assay Testing Parameters

PPD

Emerging areas of pharmaceutical research not only bring novel opportunities but also new regulatory guidance. It is this kind of familiarity and knowledge of FDA filings that an experienced provider can offer their clients to save both time and money, while avoiding bottlenecks with future filings.